Exp. | Group Condition | mAb Dose (mg/mouse) | n | Mean survival (Days) | Median Survival (Days) | Survive1 | P value2 |
---|---|---|---|---|---|---|---|
I | PBS | Â | 8 | 4.13 | 4 | 0 | Â |
 | 64F8 (IgG1) | 0.25 | 8 | 5.75 | 4 | 1 | .14 |
 | 64F8 | 0.5 | 8 | 4.88 | 4 | 0 | .10 |
 | 64F8 | 1.0 | 8 | 7.25 | 5 | 2 | .02 |
 | 80C9 (IgM) | 0.25 | 8 | 8.25 | 4 | 3 | .05 |
 | 80C9 | 0.5 | 8 | 5.88 | 4 | 1 | .09 |
 | 80C9 | 1.0 | 8 | 4.50 | 4 | 0 | .20 |
 | 64F8 + 80C9 | 0.5 + 0.5 | 4 | 8.0 | 6 | 1 | 0.002 |
II | PBS | Â | 10 | 5.40 | 5 | 0 | Â |
 | 53C2 (IgM) | 0.1 | 10 | 8.40 | 6 | 1 | 0.02 |
III | PBS | Â | 10 | 3.90 | 4 | 0 | Â |
 | 64F8 + 16G2 (IgG1+IgG2b) | 0.1 + 0.1 | 10 | 4.60 | 4 | 0 | 0.023 |
 | 64F8 + 53C2 (IgG1+gM) | 0.1 + 0.1 | 10 | 4.20 | 4 | 1 | 0.44 |
 | 64F8 + 80C9 (IgG1+IgM) | 0.1 + 0.1 | 10 | 4.70 | 4 | 0 | 0.09 |
IV | PBS | Â | 10 | 5.20 | 5 | 0 | Â |
 | 64F8 (IgM) | 0.1 | 10 | 6.90 | 6 | 1 | 0.06 |
 | 80C9 (IgM) | 0.1 | 10 | 8.10 | 6 | 2 | 0.03 |
 | 64F8 + 80C9 | 0.1 + 0.1 | 10 | 7.30 | 7 | 1 | 0.01 |